About MiNK Therapeutics, Inc.


  • Ticker INKT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 33,775,100
  • Market Cap $24.3M
  • Description
  • MiNK Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy...
More about INKT
Track This Portfolio

Track Stone X Group Inc. Portfolio

Follow Stone X Group Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Stone X Group Inc., based on Form 13F filings with the SEC.

News

Stay updated on Stone X Group Inc. with notifications on news.